Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sterilucent is a private U.S. medical device company developing low-temperature vaporized hydrogen peroxide sterilization and decontamination systems for life sciences and industrial applications. Its lead commercialized system is the MOXIsmart Life Science Processing System, which uses the company’s patented iQVHP technology to optimize hydrogen peroxide delivery, moisture sensing, drying, and cycle control. The company positions its technology as a data-driven alternative to conventional VHP systems, with an emphasis on processing sensitive lab materials, medical devices, packaging components, sensors, and other fragile instruments. Sterilucent was founded in 2004 and has been backed by NIH-related funding, Department of Defense interest, and angel investors. Although the company discusses applications relevant to medical devices, its website states that its current system is not cleared or approved by the U.S. FDA for use in healthcare or hospital environments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sterilucent.